HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Minodronate for the treatment of osteoporosis.

Abstract
Minodronate, a new nitrogen-containing bisphosphonate, was developed in Japan. It was the first drug to demonstrate significant prevention of vertebral fractures in Japanese patients with osteoporosis in a phase III doubleblind comparative study. As a result of positive data from clinical trials in Japan minodronate was granted a Japanese marketing approval for the treatment of osteoporosis on January 21, 2009. In vitro studies demonstrated that minodronate is one of the most potent inhibitors of bone resorption among currently available bisphosphonates. Preclinical studies demonstrated the inhibitory effect of minodronate on the decrease in the bone mineral density (BMD) in ovariectomized rats, dogs and monkeys. Daily oral minodronate was safe, well tolerated and effective in reducing vertebral fracture risk in postmenopausal women with established osteoporosis. The effects on lumbar and hip BMD and the safety profile of minodronate are comparable to those of alendronate. These data suggest that minodronate is a promising new potent bisphosphonate for the treatment of osteoporosis.
AuthorsTadahiko Kubo, Shoji Shimose, Toshihiro Matsuo, Jun Fujimori, Mitsuo Ochi
JournalDrugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 46 Issue 1 Pg. 33-7 (Jan 2010) ISSN: 1699-3993 [Print] Spain
PMID20200694 (Publication Type: Journal Article)
CopyrightCopyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.
Chemical References
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • YM 529
Topics
  • Animals
  • Bone Density (drug effects)
  • Bone Density Conservation Agents (adverse effects, pharmacology, therapeutic use)
  • Clinical Trials as Topic
  • Diphosphonates (adverse effects, pharmacology, therapeutic use)
  • Dogs
  • Drug Evaluation, Preclinical
  • Female
  • Fractures, Bone (prevention & control)
  • Haplorhini
  • Humans
  • Imidazoles (adverse effects, pharmacology, therapeutic use)
  • Osteoporosis (complications, drug therapy, physiopathology)
  • Rats

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: